In 2014, NephroCheck®, based on urinary [TIMP-2]*[IGFBP7], was approved by U.S. Food and Drug Administration (FDA) for marketing as a biomarker test for early detection of AKI. The gene discussed is TIMP2; the disease is acute kidney injury.